Chit Chat Stocks Huge Opportunity (HIMS) In The Peptide Market? Why Hims & Hers Stock May Benefit + Healthcare Industry Implications
Apr 15, 2026
Travis Hoium, founder of Asymmetric Investing and former Motley Fool writer, explores the rise of peptides and their potential to reshape healthcare. He discusses GLP-1 economics, regulatory and safety questions, which industries could be disrupted, and how a consumer-focused healthcare company might capitalize through personalized care and data-driven services.
AI Snips
Chapters
Transcript
Episode notes
Peptides Are Tiny Biological Messengers With Big Potential
- Peptides are short chains of 2–50 amino acids that act as biological messengers and include drugs like GLP-1s and insulin.
- Many peptides already exist naturally and can be cheap to produce, enabling potential high-frequency, personalized treatments.
GLP-1s Are A Massive Fast-Growing Pharmaceutical Category
- GLP-1 drugs like Ozempic and Wegovy drove ~ $20 billion in revenue last quarter and are the fastest-growing drugs in pharmaceutical history.
- Their rapid adoption is already reshaping consumer categories like restaurants and other consumer brands.
Position For Platforms That Combine Data AI And Compounding
- Watch telehealth platforms like Hims & Hers that can combine data, AI, and compounding to deliver personalized peptide stacks at scale.
- These platforms can ingest wearables, labs, and genomics to continuously tune treatments beyond traditional doctor workflows.